Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.NEWTON, Mass., Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY.
马萨诸塞州牛顿，2024年11月25日，Karyopharm Therapeutics公司（纳斯达克：KPTI）是一家商业阶段的药品公司，开创了新型癌症疗法，今天宣布公司的高级管理团队将参加派杰投资第36届年度医疗保健大会，在纽约时间12月3日上午11:30进行炉边聊天。纽约，纽约州。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, , and will be available for replay following the event.
可以在公司网站的投资者部分的“事件与演示文稿”下访问炉边聊天的现场网络广播，并在活动结束后提供回放。
About Karyopharm Therapeutics
关于Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics公司（纳斯达克：KPTI）是一家商业阶段的药品公司，致力于开创新型癌症疗法，其动力来自对癌症患者非凡的力量和勇气的信仰。自成立以来，Karyopharm一直是口服化合物领域的行业领导者，涉及核蛋白输出失调，这是癌症发生的基本机制。Karyopharm的首个口服输出蛋白1（XPO1）抑制剂和首创药物XPOVIO（西立诺司）在美国获批，由公司在三个肿瘤治疗适应症中销售。它还在越来越多的非美国领土和国家，包括欧洲、英国（作为NEXPOVIO）和中国，获得了各种适应症的监管批准。Karyopharm专注于多种高度不满足需求的癌症适应症，包括多发性骨髓瘤、子宫内膜癌、骨髓纤维化和弥漫大B细胞淋巴瘤（DLBCL）。有关我们的人员、科学和管线的更多信息，请访问 ，并在领英和X上关注我们@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的注册商标。本新闻稿中提到的任何其他商标均为其各自所有者的财产。
SOURCE Karyopharm Therapeutics Inc.
来源：karyopharm therapeutics公司
